Gritstone Oncology, Inc. (GRTS): Price and Financial Metrics
GET POWR RATINGS... FREE!
GRTS POWR Grades
- Sentiment is the dimension where GRTS ranks best; there it ranks ahead of 83.41% of US stocks.
- The strongest trend for GRTS is in Quality, which has been heading down over the past 177 days.
- GRTS ranks lowest in Momentum; there it ranks in the 5th percentile.
GRTS Stock Summary
- Of note is the ratio of GRITSTONE BIO INC's sales and general administrative expense to its total operating expenses; merely 8.84% of US stocks have a lower such ratio.
- With a price/sales ratio of 13.52, GRITSTONE BIO INC has a higher such ratio than 91.51% of stocks in our set.
- As for revenue growth, note that GRTS's revenue has grown -59.68% over the past 12 months; that beats the revenue growth of just 3.1% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to GRITSTONE BIO INC are LPTX, TNGX, ALPN, ALT, and CLLS.
- GRTS's SEC filings can be seen here. And to visit GRITSTONE BIO INC's official web site, go to gritstonebio.com.
GRTS Valuation Summary
- GRTS's EV/EBIT ratio is -1.9; this is 119.19% lower than that of the median Healthcare stock.
- Over the past 52 months, GRTS's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for GRTS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| GRTS | 2023-01-20 | 13.7 | 1.9 | -2.2 | -1.9 |
| GRTS | 2023-01-19 | 13.6 | 1.9 | -2.2 | -1.9 |
| GRTS | 2023-01-18 | 13.6 | 1.9 | -2.1 | -1.9 |
| GRTS | 2023-01-17 | 14.7 | 2.0 | -2.3 | -2.1 |
| GRTS | 2023-01-13 | 15.0 | 2.1 | -2.4 | -2.1 |
| GRTS | 2023-01-12 | 15.3 | 2.1 | -2.4 | -2.2 |
GRTS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- GRTS has a Quality Grade of D, ranking ahead of 22.21% of graded US stocks.
- GRTS's asset turnover comes in at 0.193 -- ranking 203rd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows GRTS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.193 | 1 | -0.623 |
| 2021-06-30 | 0.220 | 1 | -0.671 |
| 2021-03-31 | 0.231 | 1 | -0.816 |
| 2020-12-31 | 0.025 | 1 | -1.309 |
| 2020-09-30 | 0.023 | 1 | -1.050 |
| 2020-06-30 | 0.021 | 1 | -1.011 |
GRTS Price Target
For more insight on analysts targets of GRTS, see our GRTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.33 | Average Broker Recommendation | 1.5 (Moderate Buy) |
GRTS Stock Price Chart Interactive Chart >
GRTS Price/Volume Stats
| Current price | $3.18 | 52-week high | $6.10 |
| Prev. close | $3.17 | 52-week low | $1.71 |
| Day low | $3.17 | Volume | 429,908 |
| Day high | $3.28 | Avg. volume | 707,455 |
| 50-day MA | $3.22 | Dividend yield | N/A |
| 200-day MA | $2.89 | Market Cap | 265.10M |
Gritstone Oncology, Inc. (GRTS) Company Bio
Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.
Latest GRTS News From Around the Web
Below are the latest news stories about GRITSTONE BIO INC that investors may wish to consider to help them evaluate GRTS as an investment opportunity.
Investors in Gritstone bio (NASDAQ:GRTS) have unfortunately lost 66% over the last three yearsIt is doubtless a positive to see that the Gritstone bio, Inc. ( NASDAQ:GRTS ) share price has gained some 32% in the... |
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 28,000 shares of its common stock with an exercise price of $3.67, which is equal to the closing price of Gritstone’s common stock on January 9, 2023, the date of the grant. These stock |
Gritstone bio (GRTS) Presents at the 41st Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:GRTS)The following slide deck was published by Gritstone bio, Inc. |
Gritstone bio to Participate in Upcoming Investor ConferencesEMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that management will participate in the following investor conferences. B. Riley Securities' 3rd Annual Oncology Conference (Fireside Chat)Date and Time: Thursday, January 19, 2023 at 12:30pm ETPresenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer 2023 BIO CEO & Inve |
Gritstone bio Inc. (GRTS) deserves closer scrutinyAs of Friday, Gritstone bio Inc.’s (NASDAQ:GRTS) stock closed at $3.38, down from $3.45 the previous day. While Gritstone bio Inc. has underperformed by -2.03%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, GRTS fell by -48.48%, with highs and lows ranging from $6.68 to $1.71, […] |
GRTS Price Returns
| 1-mo | -7.83% |
| 3-mo | 10.80% |
| 6-mo | -6.47% |
| 1-year | -41.76% |
| 3-year | -64.11% |
| 5-year | N/A |
| YTD | -7.83% |
| 2022 | -73.17% |
| 2021 | 226.40% |
| 2020 | -56.08% |
| 2019 | -41.94% |
| 2018 | N/A |
Continue Researching GRTS
Here are a few links from around the web to help you further your research on Gritstone Oncology Inc's stock as an investment opportunity:Gritstone Oncology Inc (GRTS) Stock Price | Nasdaq
Gritstone Oncology Inc (GRTS) Stock Quote, History and News - Yahoo Finance
Gritstone Oncology Inc (GRTS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...